Antiplatelet agents for the treatment and prevention of atherothrombosis

Carlo Patrono; Felicita Andreotti; Harald Arnesen; Lina Badimon; Colin Baigent; Jean-Philippe Collet; Raffaele De Caterina; Dietrich Gulba; Kurt Huber; Steen Husted; Steen Dalby Kristensen; João Morais; Franz-Josef Neumann; Lars Hvilsted Rasmussen; Agneta Siegbahn; Philippe-Gabriel Steg; Robert F Storey; Frans Van de Werf; Freek Verheugt

doi:10.1093/eurheartj/ehr373

Antiplatelet agents for the treatment and prevention of atherothrombosis

Carlo Patrono, Felicita Andreotti, Harald Arnesen, Lina Badimon, Colin Baigent, Jean-Philippe Collet, Raffaele De Caterina, Dietrich Gulba, Kurt Huber, Steen Husted, Steen Dalby Kristensen, João Morais, Franz-Josef Neumann, Lars Hvilsted Rasmussen, Agneta Siegbahn, Philippe-Gabriel Steg, Robert F Storey, Frans Van de Werf, Freek Verheugt

Institut for Klinisk Medicin - Hjertesygdomme

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Review › Forskning › peer review

Abstract

The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.

Originalsprog	Engelsk
Tidsskrift	European Heart Journal (English Edition)
Vol/bind	32
Nummer	23
Sider (fra-til)	2922-32
Antal sider	11
ISSN	0195-668X
DOI	https://doi.org/10.1093/eurheartj/ehr373
Status	Udgivet - 2011

Adgang til dokumentet

10.1093/eurheartj/ehr373

Citationsformater

Patrono, C., Andreotti, F., Arnesen, H., Badimon, L., Baigent, C., Collet, J.-P., De Caterina, R., Gulba, D., Huber, K., Husted, S., Kristensen, S. D., Morais, J., Neumann, F.-J., Rasmussen, L. H., Siegbahn, A., Steg, P.-G., Storey, R. F., Van de Werf, F., & Verheugt, F. (2011). Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal (English Edition), 32(23), 2922-32. https://doi.org/10.1093/eurheartj/ehr373

@article{d52834a350ad47f39015110b3168342f,

title = "Antiplatelet agents for the treatment and prevention of atherothrombosis",

abstract = "The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.",

author = "Carlo Patrono and Felicita Andreotti and Harald Arnesen and Lina Badimon and Colin Baigent and Jean-Philippe Collet and {De Caterina}, Raffaele and Dietrich Gulba and Kurt Huber and Steen Husted and Kristensen, {Steen Dalby} and Jo{\~a}o Morais and Franz-Josef Neumann and Rasmussen, {Lars Hvilsted} and Agneta Siegbahn and Philippe-Gabriel Steg and Storey, {Robert F} and {Van de Werf}, Frans and Freek Verheugt",

year = "2011",

doi = "10.1093/eurheartj/ehr373",

language = "English",

volume = "32",

pages = "2922--32",

journal = "European Heart Journal (English Edition)",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "23",

}

Patrono, C, Andreotti, F, Arnesen, H, Badimon, L, Baigent, C, Collet, J-P, De Caterina, R, Gulba, D, Huber, K, Husted, S, Kristensen, SD, Morais, J, Neumann, F-J, Rasmussen, LH, Siegbahn, A, Steg, P-G, Storey, RF, Van de Werf, F & Verheugt, F 2011, 'Antiplatelet agents for the treatment and prevention of atherothrombosis', European Heart Journal (English Edition), bind 32, nr. 23, s. 2922-32. https://doi.org/10.1093/eurheartj/ehr373

TY - JOUR

T1 - Antiplatelet agents for the treatment and prevention of atherothrombosis

AU - Patrono, Carlo

AU - Andreotti, Felicita

AU - Arnesen, Harald

AU - Badimon, Lina

AU - Baigent, Colin

AU - Collet, Jean-Philippe

AU - De Caterina, Raffaele

AU - Gulba, Dietrich

AU - Huber, Kurt

AU - Husted, Steen

AU - Kristensen, Steen Dalby

AU - Morais, João

AU - Neumann, Franz-Josef

AU - Rasmussen, Lars Hvilsted

AU - Siegbahn, Agneta

AU - Steg, Philippe-Gabriel

AU - Storey, Robert F

AU - Van de Werf, Frans

AU - Verheugt, Freek

PY - 2011

Y1 - 2011

N2 - The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.

AB - The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.

U2 - 10.1093/eurheartj/ehr373

DO - 10.1093/eurheartj/ehr373

M3 - Review

C2 - 22019823

SN - 0195-668X

VL - 32

SP - 2922

EP - 2932

JO - European Heart Journal (English Edition)

JF - European Heart Journal (English Edition)

IS - 23

ER -

Antiplatelet agents for the treatment and prevention of atherothrombosis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater